Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, UPMC, 3550 Terrace Str, Pittsburgh, PA 15261, USA.
Cell Rep. 2021 Dec 21;37(12):110156. doi: 10.1016/j.celrep.2021.110156. Epub 2021 Dec 4.
The recently emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Beta (B.1.351) and Gamma (P.1) variants of concern (VoCs) include a key mutation (N501Y) found in the Alpha (B.1.1.7) variant that enhances affinity of the spike protein for its receptor, angiotensin-converting enzyme 2 (ACE2). Additional mutations are found in these variants at residues 417 and 484 that appear to promote antibody evasion. In contrast, the Epsilon variants (B.1.427/429) lack the N501Y mutation yet exhibit antibody evasion. We have engineered spike proteins to express these receptor binding domain (RBD) VoC mutations either in isolation or in different combinations and analyze the effects using biochemical assays and cryoelectron microscopy (cryo-EM) structural analyses. Overall, our findings suggest that the emergence of new SARS-CoV-2 variant spikes can be rationalized as the result of mutations that confer increased ACE2 affinity, increased antibody evasion, or both, providing a framework to dissect the molecular factors that drive VoC evolution.
最近出现的严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)β(B.1.351)和γ(P.1)变体包括在 Alpha(B.1.1.7)变体中发现的关键突变(N501Y),该突变增强了刺突蛋白与其受体血管紧张素转化酶 2(ACE2)的亲和力。这些变体在残基 417 和 484 处还存在其他突变,似乎促进了抗体逃逸。相比之下,Epsilon 变体(B.1.427/429)缺乏 N501Y 突变,但表现出抗体逃逸。我们设计了 Spike 蛋白,以单独或组合不同方式表达这些受体结合域(RBD)变体突变,并使用生化测定和冷冻电镜(cryo-EM)结构分析来分析其影响。总的来说,我们的研究结果表明,新型 SARS-CoV-2 变体 Spike 的出现可以解释为赋予 ACE2 亲和力增加、抗体逃逸增加或两者兼有的突变的结果,为剖析驱动变体进化的分子因素提供了框架。